Vaxart Inc 's ability to collect accounts receivable sequentially worsen to 4.02, indicating more challenging environment then in the first quarter 2026, but still, it is a far cry from any concerns. Vaxart Inc 's Accounts Receivable average collection period in the Jun 30 2026 quarter, has increased to 91 days, from 84 days, in the Mar 31 2026 quarter.

If we take a look into Healthcare sector 48 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Jun 30 2026 from 472 to 473.

What is Receivable Turnover Ratio?
What is Vaxart Inc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

VXRT Receivables Turnover Ratio	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Receivable Change	14.93 %	257.11 %	328.98 %	2238 %	759.58 %
Y / Y Revenue Change	-31.58 %	87.9 %	586.46 %	1367.93 %	520.68 %
Receivable Turnover Ratio (TTM)	4.02	4.33	4.88	3.82	4.43
VXRT's Total Ranking	# 473	# 472	# 2449	# 2871	# 2563
Accounts Receivable average collection period days	91	84	75	95	82
Seq. Receivable Change	-18.03 %	12.13 %	-40.26 %	109.31 %	154.7 %
Seq. Revenue Change	-30.7 %	-62.37 %	43.95 %	82.26 %	90.31 %

Receivable Turnover Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 4
Healthcare Sector	# 49
Overall Market	# 473

Receivable Turnover Ratio Statistics
High	Average	Low
1.38	0.29	0
(Mar 31 2026)		(Mar 31 2022)

News about Vaxart Inc Receivables Turnover Ratios

Navigating Clinical Advancements and Financial Realignment Vaxart Initiates Phase 2b Evaluation of Oral COVID-19 Vacc...

Evaluation of Vaxart s Next-Generation Oral COVID-19 Vaccine: Initiation of Phase 2b Sentinel CohortVaxart Inc. has recently announced the commencement of the 400-subject sentinel cohort for its Phase 2b study, designed to scrutinize the safety, immunogenicity, and efficacy of its novel oral pill COVID-19 vaccine candidate, when juxtaposed against an approved mRNA vaccine comparator. This pivotal step underscores a significant milestone as Vaxart endeavors to introduce a groundbreaking modality for COVID-19 vaccination, expanding the horizons of vaccine administration.The primary of this sentinel portion of the Phase 2b study is to holistically evaluate the safety, immunogenicity, and efficacy of Vaxart s innovative oral pill vaccine. Initial focus will be on comprehending the immunogenic profile elicited by the oral vaccine in comparison to an established mRNA vaccine, providing a robust framework for subsequent phases of clinical assessment. Given the promising outcomes of the Phase 1 and 2a trials, the Phase 2b study is designed to further substantiate the potential of this oral vaccine in producing a comparable or superior immune response, potentially revolutionizing the approach to COVID-19 immunization.

VXRT Company Profile • Back to VXRT Efficiency Comparisons • Compare VXRT Receivables Turnover Ratio to its Competitors

Financial Statements
Vaxart Inc 's Accounts Receivable	$ 47 Millions	Visit VXRT's Balance sheet
Vaxart Inc 's Sales TTM	$ 243 Millions	Visit VXRT's Income Statement
Sources of VXRT's Revenues		Visit VXRT's Sales by Geography

Other Accounts Receivable Turnover Ratios
Biotechnology & Pharmaceuticals Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
VXRT's Receivable Turnover Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
VXRT's Growth Rates	VXRT's Roa	VXRT's Inventory Turnover Ratio	VXRT's Dividend Comparisons
VXRT's Profitability Ratios	VXRT's Roi	VXRT's Asset Turnover Ratio	VXRT's Dividend Growth
VXRT's Valuation Ratios	VXRT's Roe	VXRT's Financial Strength Ratios	VXRT's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Jun 30 2026, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Jun 30 2026	Receivable at quarter ending Jun 30 2026
Lftd Partners Inc	14.13	$ 35.335 Millions	$ 2.500 Millions
Talkspace Inc	14.09	$ 246.631 Millions	$ 17.506 Millions
Lifestance Health Group Inc	14.07	$ 1,584.834 Millions	$ 112.665 Millions
Ataibeckley Inc	13.83	$ 4.473 Millions	$ 0.324 Millions
Amneal Pharmaceuticals Inc	13.83	$ 3,117.474 Millions	$ 225.492 Millions
Arvinas Inc	13.49	$ 316.700 Millions	$ 23.475 Millions
Rosecliff Acquisition Corp I	13.43	$ 16.467 Millions	$ 1.226 Millions
Corcept Therapeutics Inc	13.30	$ 830.813 Millions	$ 62.477 Millions
Precipio inc	13.25	$ 27.198 Millions	$ 2.052 Millions
Skinhealth Systems Inc	13.04	$ 289.224 Millions	$ 22.179 Millions
Chemed Corporation	12.94	$ 2,595.001 Millions	$ 200.565 Millions
Qhslab Inc	12.77	$ 3.017 Millions	$ 0.236 Millions
Petvivo Holdings Inc	12.34	$ 1.182 Millions	$ 0.096 Millions
Alpha Pro Tech Ltd	12.25	$ 62.204 Millions	$ 5.077 Millions
Vivos Therapeutics Inc	12.21	$ 21.135 Millions	$ 1.731 Millions
Milestone Scientific Inc	11.82	$ 8.855 Millions	$ 0.749 Millions
Marpai Inc	11.71	$ 16.635 Millions	$ 1.420 Millions
Catheter Precision Inc	11.62	$ 1.915 Millions	$ 0.165 Millions
Nrc Health	11.35	$ 139.996 Millions	$ 12.337 Millions
Picard Medical Inc	11.34	$ 5.983 Millions	$ 0.528 Millions
Veracyte Inc	11.07	$ 544.735 Millions	$ 49.194 Millions
International Stem Cell Corporation	10.91	$ 9.514 Millions	$ 0.872 Millions
Premier Air Charter Holdings Inc	10.66	$ 31.562 Millions	$ 2.961 Millions
C4 Therapeutics Inc	10.65	$ 35.039 Millions	$ 3.290 Millions
Lifeloc Technologies Inc	10.48	$ 9.269 Millions	$ 0.884 Millions
Irhythm Holdings Inc	10.32	$ 825.702 Millions	$ 80.007 Millions
Immucell Corporation	10.29	$ 29.777 Millions	$ 2.893 Millions
Addus Homecare Corp	10.23	$ 1,475.610 Millions	$ 144.195 Millions
Dariohealth Corp	10.23	$ 21.196 Millions	$ 2.072 Millions
Radnet Inc	10.11	$ 2,268.932 Millions	$ 224.447 Millions

Date modified: 2026-09-01T20:16:20+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.